Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
Most advanced non-small cell lung cancer (NSCLC) patients are accompanied by brain metastasis which is the major cause of increased mortality. The fusion rearrangement of anaplastic lymphoma kinase (ALK) gene is an important feature of brain metastasis in lung cancer. The novel ALK inhibitors alect...
Main Authors: | Xu Feng, En-Shi Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2021-06-01
|
Series: | Biomolecules & Biomedicine |
Subjects: | |
Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/5066 |
Similar Items
-
Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
by: Stefano Testa, et al.
Published: (2021-06-01) -
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01) -
Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report
by: James A. Fletcher, M.B.B.S., et al.
Published: (2024-02-01) -
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
by: Lee AT, et al.
Published: (2023-07-01) -
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)